The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype
- PMID: 28762114
- PMCID: PMC5697709
- DOI: 10.1245/s10434-017-6016-y
The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype
Abstract
Background: Strategies to reduce the likelihood of axillary lymph node dissection (ALND) include application of Z0011 or use of neoadjuvant chemotherapy (NAC). Indications for ALND differ by treatment plan, and nodal pathologic complete response rates after NAC vary by tumor subtype. This study compared ALND rates for cT1-2N0 tumors treated with upfront surgery versus those treated with NAC.
Methods: The ALND rates for cT1-2N0 breast cancer patients were compared by tumor subtype among women undergoing upfront surgery to NAC. Multivariable analysis with control for age, cT stage, and lymphovascular invasion, and stratification by subtype was performed.
Results: The study identified 1944 cancers in 1907 women who underwent sentinel lymph node (SLN) biopsy with or without ALND (669 upfront breast-conserving surgeries [BCSs], 1004 upfront mastectomies, 271 NACs). Compared with the NAC group, the ALND rates in the BCS group were lower for estrogen receptor (ER), progesterone receptor-positive (PR+), human epidermal growth factor 2-negative (HER2-) tumors (15 vs 34%; p < 0.001). The ALND rates in the upfront mastectomy group were higher than in the NAC group for HER2+ or TN tumors. In the multivariable analysis, receipt of NAC compared with upfront BCS remained significantly associated with higher odds of ALND in the ER/PR+ HER2- subtype (hazard ratio [HR], 3.35; p < 0.001), whereas NAC versus upfront mastectomy remained significantly associated with lower odds of ALND in the HER2+ and TN subtypes (HR for HER2+, 0.19, p < 0.001; HR for TN, 0.25, p = 0.007).
Conclusion: The study showed that ALND rates differ according to surgery type and tumor subtype secondary to differing ALND indications and nodal response to NAC. These factors can be used to personalize treatment planning to minimize ALND risk for patients with early-stage breast cancer.
Conflict of interest statement
The authors have no conflict of interest disclosures to report.
Figures

Similar articles
-
Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy.Ann Surg Oncol. 2025 Feb;32(2):922-930. doi: 10.1245/s10434-024-16382-7. Epub 2024 Oct 23. Ann Surg Oncol. 2025. PMID: 39441324
-
The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.Ann Surg Oncol. 2018 Oct;25(10):3019-3029. doi: 10.1245/s10434-018-6587-2. Epub 2018 Jul 5. Ann Surg Oncol. 2018. PMID: 29978365 Free PMC article.
-
Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?Ann Surg Oncol. 2016 Apr;23(4):1123-8. doi: 10.1245/s10434-015-4944-y. Epub 2015 Nov 9. Ann Surg Oncol. 2016. PMID: 26553439 Free PMC article.
-
Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2- Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis.Breast J. 2024 Aug 2;2024:8866756. doi: 10.1155/2024/8866756. eCollection 2024. Breast J. 2024. PMID: 39742366 Free PMC article.
-
Best treatment options for occult breast cancer: A meta-analysis.Front Oncol. 2023 May 12;13:1051232. doi: 10.3389/fonc.2023.1051232. eCollection 2023. Front Oncol. 2023. PMID: 37251927 Free PMC article.
Cited by
-
Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy.Ann Surg Oncol. 2020 Mar;27(3):743-749. doi: 10.1245/s10434-019-08038-8. Epub 2019 Nov 15. Ann Surg Oncol. 2020. PMID: 31732944 Free PMC article.
-
An Overview of the Importance of Neoadjuvant Systemic Therapy for Breast Cancer Patients: From the Society of Surgical Oncology and the American Society of Breast Surgeons.Ann Surg Oncol. 2025 Aug;32(8):5453-5466. doi: 10.1245/s10434-025-17405-7. Epub 2025 May 12. Ann Surg Oncol. 2025. PMID: 40355803 Review. No abstract available.
-
Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.Ann Surg Oncol. 2022 Sep;29(9):5747-5756. doi: 10.1245/s10434-022-11871-z. Epub 2022 May 15. Ann Surg Oncol. 2022. PMID: 35569077 Free PMC article.
-
Axillary Management: How Much Is Too Much?Curr Oncol Rep. 2024 Jul;26(7):735-743. doi: 10.1007/s11912-024-01539-0. Epub 2024 May 15. Curr Oncol Rep. 2024. PMID: 38748364 Free PMC article. Review.
-
Contemporary Axillary Surgical Management in Patients with Pathologically Node Positive Disease After Neoadjuvant Chemotherapy: A Survey of Members of the American Society of Breast Surgeons.Ann Surg Oncol. 2024 Oct;31(11):7362-7371. doi: 10.1245/s10434-024-15705-y. Epub 2024 Jul 8. Ann Surg Oncol. 2024. PMID: 38976157
References
-
- Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–32. discussion 432-3. - PMC - PubMed
-
- Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74. - PubMed
-
- Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–93. - PubMed
-
- Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558–66. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous